Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557855 · ClinicalTrials.gov registry record
Investigation of a Novel Gene Expression Test (ASGES or Corus CAD) for Diagnosis of Obstructive Coronary Artery Disease
A clinical trial, sponsored by CardioDx.
- Completed
- Registry status
- 342
- Enrollment target
NCT01557855: Completed study, sponsored by CardioDx.
NCT01557855 is a clinical trial that has completed, run by CardioDx. The registered enrollment target is 342 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01557855 has completed, sponsored by CardioDx.
- COMPLETED
- Registry status
- 342 participants
- Enrollment target
Study Summary
The objective of this study is to collect data on the commercial use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood test to evaluate the clinical referral patterns of Primary Care Physicians after receipt of their patients' Corus Score, and to better understand patient management patterns for clinicians ordering the test.
Primary Outcome
Composite endpoint consisting of referrals to a cardiologist, to cardiac stress/CTA and/or to invasive cardiac catheterization occurring between Day 0 and Day 30 + 15 days.
Interventions
- DIAGNOSTIC_TEST Corus CAD (ASGES)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-05 |
What the finished NCT01557855 record still lists
NCT01557855 is an observational study that tracks outcomes without assigning an intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Corus CAD (ASGES) is the first listed.
NCT01557855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01557855 about?
NCT01557855 is a clinical study titled "Investigation of a Novel Gene Expression Test (ASGES or Corus CAD) for Diagnosis of Obstructive Coronary Artery Disease". The objective of this study is to collect data on the commercial use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood test to evaluate the clinical referral patterns of Primary Care Physicians after receipt of their patients' Corus Score, and to better understand patient management pattern...
What is the current status of trial NCT01557855?
This trial is currently completed. The enrollment target is 342 participants. The study started on 2012-04. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01557855?
The interventions under investigation include: Corus CAD (ASGES) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01557855?
This trial is sponsored by CardioDx, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia